An interventional study of IDUS examination in Choledocholithiasis, Cholangiopancreatography, Endoscopic Retrograde and Ultrasonography, sponsored by Shanghai Municipal Hospital of Traditional Chinese Medicine. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-20.
Sponsored by Shanghai Municipal Hospital of Traditional Chinese Medicine · Not applicable, Interventional, and Prevention
This study is designed to observed CBD stones cases with high recurrence risks applying IDUS or not during ERCP.
Patients with CBD stone high recurrence risks were enrolled in this study, and prospectively randomized into IUDS group and control group during lithotomy.
Operation time, radiation time, hospitalization cost, retain of nasobiliary tube, deployment of stent were recorded.
Symptoms and conditions after ERCP were also followed up including blood amylase, routine blood test, abdominal pain, post-ERCP pancreatitis, resection of gallbladder, recurrence of CBD stone and onset of cholangitis.
Patients with CBD stone high recurrence risks were enrolled in this study, and prospectively randomized into IUDS group and control group during lithotomy.
High risks were defined as diameter of CBD>1.5cm, number of calculi>2, and lithotripsy.
Operation time, radiation time, hospitalization cost, retain of nasobiliary tube, deployment of stent were recorded.
Symptoms and conditions after ERCP were also followed up including blood amylase, routine blood test, abdominal pain, post-ERCP pancreatitis, resection of gallbladder, recurrence of CBD stone and onset of cholangitis.
109 studies on the registry are indexed under Choledocholithiasis; 24 are open to participants now.
This study's enrollment of 248 is above the median of 100 across 76 interventional studies indexed under Choledocholithiasis.
Browse Choledocholithiasis studies →Shanghai Municipal Hospital of Traditional Chinese Medicine is the lead sponsor of 14 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
CBD stones cases with high recurrence risks apply IDUS during ERCP
Procedure: IDUS examination
CBD stones cases with high recurrence risks don't apply IDUS during ERCP
for patients with high risks of bile duct stones recurrence using IDUS during ERCP
recurrence of bile duct stone or cholangitis
patients will be followed up for 48 weeks to record the recurrence of CBD stones or cholangitis
Time frame: 48 weeks
need for a nasobiliary tube
it's a Yes or No categorical variable to describe if the patient was placed a nasobiliary tube during ERCP
Time frame: 2 weeks
need for stents
it's a Yes or No categorical variable to describe if stents were deployed during ERCP
Time frame: 4 weeks
operation time
the time from tracheal intubation to the end of ERCP was recorded
Time frame: intraoperative
radiation time
radiation time of each patient was recorded
Time frame: 4 weeks
hospitalization cost
hospitalization cost of each patient was recorded
Time frame: 8 weeks
Questionnaire of Symptoms and conditions after ERCP
Questionnaire of symptoms and conditions after ERCP were recorded. Degree of abdominal pain and distension were recorded with a highest level of three points respectively.
Time frame: 8 weeks
White blood cell count
Routine blood test
Time frame: 12 weeks
Red blood cell count
Routine blood test
Time frame: 12 weeks
Platelet count
Routine blood test
Time frame: 12 weeks
total bilirubin, direct bilirubin
Liver function test
Time frame: 12 weeks
Liver function test (ALT, AST)
Time frame: 12 weeks
albumin
Liver function test
Time frame: 12 weeks
total protein
Liver function test
Time frame: 12 weeks
Gamma-glutamyl transferase (GGT) test
Liver function test
Time frame: 12 weeks
An alkaline phosphatase (ALP) test
Liver function
Time frame: 12 weeks
whether have a resection of gallbladder checklist
whether the patient has a resection of gallbladder after ERCP
Time frame: 48 weeks
Ran from Nov 2021 to primary completion in Jan 2024, 26 months.
Of 41 non-industry interventional studies with no phase under Choledocholithiasis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 26 months is above that.
Counting every sponsor, half of 43 studies reached it within 21 months; a quarter within 12 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Municipal Hospital of Traditional Chinese Medicine